Search

everythinglearnresearchcommunity

for

Search:↓

Online articles about alopecia areata are too hard to understand and need to be clearer.

Alopecia areata patients don't have increased atherosclerosis risk, but may have higher cardiovascular risk due to smoking, blood sugar, and blood pressure.

Hair loss from alopecia areata and androgenetic alopecia moderately affects the quality of life, especially in younger patients and those with long-term hair loss, impacting both their physical and emotional well-being.

People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.

80% scalp hair regrowth is a successful treatment for alopecia areata.

Higher IL-21 levels may help predict alopecia areata activity.

High-quality validation studies are needed to improve alopecia areata patient-reported outcome measures.

The Spanish version of the Hair Specific Skindex-29 scale is a reliable and valid way to measure the impact of hair loss on women's quality of life.

Alopecia areata greatly harms quality of life, causing emotional and social issues.

Hair thickness differences help diagnose hair loss severity.

Alopecia areata significantly affects emotional well-being and daily activities, suggesting a need for patient-centered care.

Understanding how cells die in the skin is important for treating skin diseases and preventing hair loss.

Patients with alopecia areata might have a lower risk of stroke and possibly heart attack.

Women with alopecia areata have poor blood flow, possibly due to nerve inflammation.

Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.

Certain blood cell ratios are higher in kids with alopecia areata and might help predict the disease.

Alopecia areata patients have a higher risk of subclinical atherosclerosis, and carotid ultrasound can help assess their cardiovascular risk.

Hair loss lowers quality of life, causing embarrassment, frustration, and sexual rejection.

Self-assessed hirsutism scores are not reliable for clinical diagnosis but may help in screening.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.

The modified Sinclair scale effectively measures hair loss severity in men.

Standardized assessment tools for androgenetic alopecia are needed.

Patients often overestimate their skin type, affecting sun protection and treatment plans.

The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.

Patients with anxiety or depression report more severe alopecia areata.

More lesions mean more severe alopecia areata.

Patients with Alopecia Areata are willing to trade life duration for better quality of life.

New scale reliably assesses male hair loss with female pattern.

Dermoscopy is useful for tracking alopecia areata treatment, with yellow dots and new vellus hairs being good indicators of hair regrowth.

Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.